Guardant Health Japan Corp submits regulatory application for Guardant360 CDx

Guardant Health Japan Corp announced its submission of a regulatory application to Japan’s Ministry of Health, Labour and Welfare (MHLW) for the approval of the Guardant360® CDx comprehensive genomic profiling panel. This submission aims to use the panel as a companion diagnostic for Janssen Pharmaceutical K.K.’s amivantamab-vmjw, in combination with chemotherapy, for patients with inoperable or recurrent non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Janssen Pharmaceutical is currently seeking regulatory approval for this precision medicine in Japan.

Lung cancer is one of the most common and lethal cancers worldwide, with NSCLC accounting for approximately 80-85% of all lung cancer cases. In Japan, over 136,000 new cases of lung cancer were diagnosed in 2022. If approved, this regulatory application would enhance access to targeted treatment options for patients in Japan with inoperable or recurrent NSCLC harbouring EGFR exon 20 insertion mutations. It would also mark Guardant360 CDx as the first blood-based companion diagnostic approved in Japan for detecting EGFR exon 20 insertion mutations.

The Guardant360® CDx was previously approved by the MHLW in March 2022 for comprehensive genomic profiling in patients with advanced solid tumours. This test examines 74 cancer-related genes and is approved as a companion diagnostic for multiple cancer drugs in Japan.

The approval of the Guardant360® CDx as a companion diagnostic for amivantamab-vmjw would represent a significant advancement in the availability of precision medicine for lung cancer patients in Japan.

EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases. EDX Medical entered into a strategic agreement with Guardant Health Inc., under which they distribute Guardant360® CDx and Guardant Reveal™.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
EDX Medical Group plc

More articles like this

EDX Medical Group plc

Liquid biopsy in cancer detection and treatment

Recent years have seen liquid biopsy making significant strides in the healthcare landscape, especially for cancer detection. Known also as multi-cancer detection (MCD) or MCD assays, this test screens for various cancers using just a blood

EDX Medical Group plc

EDX Medical Chairman and Founder provide shareholder update

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, has announced that Jason Holt, Chairman of the Company, and Prof. Sir Chris Evans, Founder

EDX Medical Group plc

EDX Medical signs distribution agreement with Caris Life Sciences

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced it has signed a distribution agreement with Caris Life Sciences® (Caris), a leading US-based next-generation

EDX Medical Group plc

EDX Medical gains strong backing to revolutionise healthcare

Andrew Lloyd Webber, renowned for his iconic musicals, has invested in EDX Medical, a pioneering company focused on transforming the diagnosis and treatment of cancer, heart disease, and hospital infections. Founded by scientist Sir Chris Evans

EDX Medical Group plc

Understanding cancer’s genetic origins

Cancer is fundamentally a genetic disease caused by alterations in the genes that regulate cell growth and reproduction. These alterations, or mutations, can occur due to several factors, such as random errors during cell division, exposure

EDX Medical Group plc

Understanding how genetics influence cancer risk

Your genome, an extensive set of genetic material composed of approximately 3 billion pieces of DNA, serves as the master instruction manual for your body. Every cell within your body contains this entire genome. If you

EDX Medical Group plc

Understanding genetic testing and its role in cancer risk

Genetic testing involves medical tests to identify specific mutations in a person’s genes. These tests, which are continually evolving, have diverse applications, including assessing cancer risk. Predictive genetic testing, in particular, looks for inherited gene mutations

EDX Medical Group plc

EDX Medical Group participating in “The Pub Test” Investor Evening

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced its participation in “The Pub Test” Investor Evening. This event is co-hosted